Literature DB >> 7644565

Interleukin-1 in the treatment of cancer.

B D Curti1, J W Smith.   

Abstract

Interleukin-1 (IL-1) is a cytokine with many activities central to immune function and hematopoiesis. Many IL-1 properties can be potentially exploited in the treatment of malignancy. This review describes the toxicities and antitumor effects observed in Phase I and II trials of IL-1 in cancer patients. The immunophysiology and the induction of cytokines by IL-1 has been examined in many of the Phase I trials and has aided in understanding IL-1 effects in humans. The influence of IL-1 on granulopoiesis and thrombopoiesis when given by different regimes is also reviewed in detail.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7644565     DOI： 10.1016/0163-7258(95)98595-h

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN： 0163-7258            Impact factor:   12.310


  4 in total

Review 1.  Clinical toxicity of cytokines used as haemopoietic growth factors.

Authors:  T Vial; J Descotes
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

2.  Enterovirus related metabolic myopathy: a postviral fatigue syndrome.

Authors:  R J M Lane; B A Soteriou; H Zhang; L C Archard
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-10       Impact factor: 10.154

Review 3.  Cytokines in parvovirus B19 infection as an aid to understanding chronic fatigue syndrome.

Authors:  Jonathan R Kerr; David A J Tyrrell
Journal:  Curr Pain Headache Rep       Date:  2003-10

4.  Multilineage hematopoietic recovery with concomitant antitumor effects using low dose Interleukin-12 in myelosuppressed tumor-bearing mice.

Authors:  Lena A Basile; Timothy K Gallaher; Darryl Shibata; Joseph D Miller; Dan Douer
Journal:  J Transl Med       Date:  2008-05-19       Impact factor: 5.531
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.